Martin Hutchings

Professor

University of Copenhagen

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Martin Hutchings is a Professor at the University of Copenhagen, Denmark. His research focuses on hematological malignancies, particularly the role of circulating tumor DNA in relapsed and refractory lymphomas and acute myeloid leukemia. He has contributed to studies on the prevalence of sarcopenia in lymphoma patients and the long-term follow-up of treatment strategies in mantle cell lymphoma and Hodgkin lymphoma.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (14)

Ingrid Glimelius

SWEDEN

View details

Tarec Christoffer El‐Galaly

DENMARK

View details

Mehdi Hamadani

UNITED STATES

View details

Rose-Marie Amini

SWEDEN

View details

Sara Ek

SWEDEN

View details

Pieternella J. Lugtenburg

University Medical Center

NETHERLANDS

View details

Maja Vestmø Maraldo

Copenhagen University Hospital

DENMARK

View details

Simon Husby

University of Copenhagen

DENMARK

View details

Karin E. Smedby

SWEDEN

View details

Thoas Fioretos

Professor, senior consultant

Lund University Medical Faculty

SWEDEN

View details

Tycel Phillips

University of Michigan Medical School

UNITED STATES

View details

Jan Christensen

Københavns Universitet

DENMARK

View details

Anna Porwit

Professor

Lund University

SWEDEN

View details

Daniel Molin

Associate Professor

Uppsala University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martin Hutchings

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma

The effectiveness of exercise-based interventions on muscle mass, muscle strength, functional performance, aerobic capacity, and health-related quality of life in adults with malignant lymphoma undergoing chemotherapy

NOTCH1 Mutations Are Associated With Therapy-Resistance in Patients With B-Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies

Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Prevalence of Pre-Treatment Sarcopenia in Patients newly diagnosed with Lymphoma

High‐dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited‐stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long‐term follow‐up of the Nordic Lymphoma Group MCL6 Philemon trial

Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register‐Based Cohort Study

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study

Novel precision medicine approaches and treatment strategies in hematological malignancies

Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials

The evolving therapy of DLBCL: Bispecific antibodies

European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Collaborators (14)

Ingrid Glimelius

Tarec Christoffer El‐Galaly

Mehdi Hamadani

Rose-Marie Amini

Sara Ek

Pieternella J. Lugtenburg

Maja Vestmø Maraldo

Simon Husby

Karin E. Smedby

Thoas Fioretos

Tycel Phillips

Jan Christensen

Anna Porwit

Daniel Molin

Make your next move.